Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2016

View Archived Issues

MedImmune and Abpro to collaborate in developing bispecific antibody

Positive interim data of phase II study of inclisiran at 90 days

Preclinical data on RG-7386 in solid tumors

CytRx reports updated findings from phase III trial of aldoxorubicin for soft tissue sarcomas

Voyager Therapeutics exercises options for rights to NAV vectors

TPC-107, shows high efficacy in cancer tumor mouse models

A tetravalent vaccine candidate against lymphatic filariasis

First-in-human trial finds synthetic preimplantation factor safe and well tolerated

Global Blood Therapeutics' GBT-440 granted orphan designation in E.U.

Ultragenyx Pharmaceutical reports 78-week data from phase II study of UX-007

FDA clears IND for KN-035

Viracta Therapeutics completes acquisition of HDAC inhibitor from Chroma Therapeutics

Bicycle Therapeutics establishes bicyclic peptide collaboration with AstraZeneca

BiondVax's universal flu vaccine safe, well tolerated in phase II study

FDA accepts for review sNDA for expanded label of Abilify Maintena

FDA grants orphan drug designation to risankizumab

Chugai files for approval of Actemra for additional indication in Japan

Naia submits IND application to initiate phase Ib trial of NB-1001 in short bowel syndrome

Five of ProMIS Neurosciences' MAbs for Alzheimer's block prion-like propagation

Bioavailability results presented for GSP-301 at ACAAI

Committee recommends continuation of phase III study of ThermoDox in liver cancer

MicuRx Pharmaceuticals begins phase I study of MRX-4

Tangrun Pharmaceuticals patents agents for HCV infection

Australian institutes describe IRAP inhibitors

Selvita reports PFKFB inhibitors in patent

Roche patent describes TLR7 agonists for HBV infections

Boehringer Ingelheim prepares and tests IGF-1R inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...